Rocket Pharmaceuticals is a biotech company that develops a pipeline of genetic therapies for rare childhood disorders.
Rocket Pharmaceuticals is a biotechnology company that is working to develop first-in-class gene therapy treatments for rare and undertreated diseases. The Company's lead program is a lentiviral-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult-to-treat genetic disease that causes bone marrow failure and, in the worst-case scenario, cancer. Additional bone marrow-derived disorders are being studied in preclinical trials, including Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-1 (LAD-1), and Infantile Malignant Osteopetrosis. In addition, the company is working on an AAV-based gene therapy program for an unnamed rare pediatric disease.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 3, 2022 | Post-IPO Equity | $100.30M | — | — | — | Detail |
Aug 30, 2021 | Post-IPO Equity | $26.40M | 1 | RTW Investments | — | Detail |
Dec 9, 2020 | Post-IPO Equity | $299M | 1 | — | — | Detail |
Nov 13, 2020 | Grant | $3.70M | 1 | California Institute of Regenerative Medicine (CIRM) | — | Detail |
Dec 10, 2019 | Post-IPO Equity | $84.99M | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
RTW Investments | Yes | Post-IPO Equity |
California Institute of Regenerative Medicine (CIRM) | Yes | Grant |
Frazier Healthcare Partners | — | Post-IPO Equity |
Civilization Ventures | — | Post-IPO Equity |
Sahsen Ventures | — | Post-IPO Equity |
Rocket Pharmaceuticals has acquired 2 organizations. Their most recent acquisition was Inotek Pharmaceuticals on Sep 12, 2017. They acquired Inotek Pharmaceuticals for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Sep 12, 2017
Inotek Pharmaceuticals
|
Biotechnology | acquisition | — | Detail |
Sep 20, 2022
Renovacor
|
Biotechnology | acquisition | — | Detail |